# Janssen Research & Development, LLC: Phase 1 study closed enrollment, 751 enrolled (Non-Small-Cell Lung Cancer)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer |
| NCT ID | NCT02609776 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Non-Small-Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 751 |
| Site countries | United States, Australia, Canada, China, France, Japan, South Korea, Spain, Taiwan, United Kingdom |
| Posted | 2015-11-20 |
| Planned start | 2016-05-24 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 751 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT02609776). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.